BACKGROUND AND OBJECTIVES: Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D. RESULTS: Median GFR was 66.5 (interquartile range, 40.0-88.3) ml/min per 1.73 m(2). Median sclerostin level was 53.5 (interquartile range, 37.5-77.2) pmol/L, was higher in patients with a GFR <60 ml/min per 1.73 m(2), and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (P<0.05). An inverse relationship was found between sclerostin and GFR (r=-0.58; P<0.001), and a positive correlation was seen with age (r=0.34; P<0.01) and serum phosphate (r=0.26; P=0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (P<0.001). Age lost its relationship with sclerostin level. CONCLUSIONS: This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.
BACKGROUND AND OBJECTIVES:Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D. RESULTS: Median GFR was 66.5 (interquartile range, 40.0-88.3) ml/min per 1.73 m(2). Median sclerostin level was 53.5 (interquartile range, 37.5-77.2) pmol/L, was higher in patients with a GFR <60 ml/min per 1.73 m(2), and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (P<0.05). An inverse relationship was found between sclerostin and GFR (r=-0.58; P<0.001), and a positive correlation was seen with age (r=0.34; P<0.01) and serum phosphate (r=0.26; P=0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (P<0.001). Age lost its relationship with sclerostin level. CONCLUSIONS: This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.
Authors: Michelle M McDonald; Alyson Morse; Kathy Mikulec; Lauren Peacock; Nicole Yu; Paul A Baldock; Oliver Birke; Min Liu; Hua Zhu Ke; David G Little Journal: J Orthop Res Date: 2012-03-27 Impact factor: 3.494
Authors: Daniel Cejka; Agnes Jäger-Lansky; Heidi Kieweg; Michael Weber; Christian Bieglmayer; Dominik G Haider; Danielle Diarra; Janina M Patsch; Franz Kainberger; Barbara Bohle; Martin Haas Journal: Nephrol Dial Transplant Date: 2011-05-25 Impact factor: 5.992
Authors: Luigi Gennari; Daniela Merlotti; Roberto Valenti; Elena Ceccarelli; Martina Ruvio; Maria G Pietrini; Cosimo Capodarca; Maria Beatrice Franci; Maria Stella Campagna; Anna Calabrò; Dorica Cataldo; Konstantinos Stolakis; Francesco Dotta; Ranuccio Nuti Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi Journal: J Bone Miner Res Date: 2012-08 Impact factor: 6.741
Authors: Karin Amrein; Steven Amrein; Camilla Drexler; Hans Peter Dimai; Harald Dobnig; Klaus Pfeifer; Andreas Tomaschitz; Thomas R Pieber; Astrid Fahrleitner-Pammer Journal: J Clin Endocrinol Metab Date: 2011-10-12 Impact factor: 5.958
Authors: Ulrike I Mödder; Kelley A Hoey; Shreyasee Amin; Louise K McCready; Sara J Achenbach; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla Journal: J Bone Miner Res Date: 2011-02 Impact factor: 6.741
Authors: Ulrike Il Mödder; Jackie A Clowes; Kelley Hoey; James M Peterson; Louise McCready; Merry Jo Oursler; B Lawrence Riggs; Sundeep Khosla Journal: J Bone Miner Res Date: 2011-01 Impact factor: 6.741
Authors: Thomas C Register; Keith A Hruska; Jasmin Divers; Donald W Bowden; Nicholette D Palmer; J Jeffrey Carr; Lynne E Wagenknecht; R Caresse Hightower; Jianzhao Xu; S Carrie Smith; Dennis J Dietzen; Carl D Langefeld; Barry I Freedman Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Gina N Woods; Susan K Ewing; Sigurdur Sigurdsson; Deborah M Kado; Joachim H Ix; Trisha F Hue; Gudny Eiriksdottir; Kaipin Xu; Vilmundur Gudnason; Thomas F Lang; Eric Vittinghoff; Tamara B Harris; Clifford J Rosen; Xiaojuan Li; Ann V Schwartz Journal: J Bone Miner Res Date: 2018-08-27 Impact factor: 6.741
Authors: S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque Journal: Osteoporos Int Date: 2015-04-25 Impact factor: 4.507
Authors: Daniel Cejka; Diego Parada-Rodriguez; Stefanie Pichler; Rodrig Marculescu; Ina Kramer; Michaela Kneissel; Thomas Gross; Andreas Reisinger; Dieter Pahr; Marie-Claude Monier-Faugere; Martin Haas; Hartmut H Malluche Journal: Kidney Int Date: 2016-08-12 Impact factor: 10.612